BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 27.04.2001

Draft Guidance for Industry; Premarket Approval Applications for In Vitro Diagnostic Devices Pertaining to Hepatitis C Viruses (HCV); Assays Intended for Diagnosis, Prognosis, or Monitoring of HCV Infection, Hepatitis C, or Other HCV-Associated Disease; Availability

The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled "Premarket Approval Applications for In Vitro Diagnostic Devices Pertaining to Hepatitis C Viruses (HCV): Assays Intended for Diagnosis, Prognosis, or Monitoring of HCV Infection, Hepatitis C, or Other HCV-Associated Disease; Draft Guidance for Industry and FDA." FDA is issuing this draft guidance to provide current recommendations about the design, data collection, and data analysis of studies that are important to the premarket approval application (PMA) process for in vitro diagnostic (IVD) devices pertaining to HCV. This draft guidance is not final nor is it in effect at this time.

Source: Federal Register — Food and Drug AdministrationOpen original release →